Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-03-08
Based on 130 first isolates · ICU · Skin / wound infection · 2025-03-09 → 2026-03-08
Intensive care unit
Per-organism detail: ICU wound resistance view →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 57 % (48 %–65 %)
Best two-drug combination: vancomycin + meropenem covers 98 % (95 %–100 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (13 %), Escherichia coli (12 %), Proteus mirabilis (6 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
57 %
47 %
n = 17
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
43 %
29 %
n = 17
meropenem MEM
trend · Pseudomonas aeruginosa reserve
42 %
47 %
n = 17
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
41 %
53 %
n = 17
36 %
35 %
n = 17
ceftriaxone CRO
trend · Escherichia coli
29 %
35 %
n = 17
28 %
35 %
n = 17
21 %
18 %
n = 17
11 %
18 %
n = 17
mecillinam MEC
not for this site
0 %
0 %
n = 17
trimethoprim TMP
not for this site
0 %
0 %
n = 17
nitrofurantoin NIT
not for this site
0 %
0 %
n = 17

Most likely organisms for this profile

Staphylococcus aureus
47 %
Pseudomonas aeruginosa
13 %
Escherichia coli
12 %
Enterococcus faecalis
10 %
Proteus mirabilis
6 %
Klebsiella pneumoniae
6 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.